Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Newsfilter· 2024-08-08 14:00
OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2024, and provides a corporate update. "We are very pleased ...
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
Newsfilter· 2024-08-08 13:32
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets.  Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering opp ...
VEON 2Q24 Trading Update: Double-Digit USD Growth, Robust Operational Execution, Confirming Full Year Guidance
Newsfilter· 2024-08-08 13:00
  VEON 2Q24 Trading Update: Double-Digit USD Growth, Robust Operational Execution, Confirming Full Year Guidance Amsterdam, 8 August 2024 07:00AM CEST VEON Q2 2024 Highlights Q2 revenue of USD 1,026 million, +12.1% YoY (+15.1% YoY in local currency) and EBITDA of USD 459 million, +10.6% YoY (+13.9% YoY in local currency) Q2 direct digital revenue of USD 108 million, +83.3% YoY (+81.4% YoY in local currency)Q2 capex of USD 181 million, +5.8% YoY, with LTM capex intensity of 18.0% Total cash and cash equival ...
ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering
Newsfilter· 2024-08-08 09:44
文章核心观点 - 公司发行2.25%到期日为2029年的可转换优先票据,总金额为2.75亿美元,并授予承销商增发4.125亿美元的选择权 [1][2] - 公司将使用部分募集资金偿还现有的有担保贷款,并将与银行签订新的有担保贷款协议 [5] - 公司还将使用部分募集资金购买与可转换票据相关的套期保值交易 [6][7][9][10] 公司概况 - 公司是一家多元化的生物制药公司,专注于开发、生产和销售高质量的处方药品,包括罕见疾病领域 [12] - 公司正在通过其主要产品Purified Cortrophin® Gel扩大罕见疾病业务,并加强仿制药业务的研发能力,同时在成熟品牌领域实现创新 [12] 融资交易 - 公司预计本次发行的净募集资金约为2.668亿美元,如果承销商行使增发选择权,则净募集资金约为3.068亿美元 [5] - 公司将使用约3530万美元的净募集资金购买与可转换票据相关的套期保值交易 [5][6][7][9][10] - 剩余的净募集资金将与公司现金一起用于偿还现有的有担保贷款 [5]
Fortuna reports financial results for the second quarter of 2024
Newsfilter· 2024-08-08 09:33
(All amounts are expressed in US dollars, tabular amounts in millions, unless otherwise stated) VANCOUVER, British Columbia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Fortuna Mining Corp. (NYSE:FSM, TSX:FVI) ("Fortuna" or the "Company") today reported its financial and operating results for the second quarter of 2024. Second Quarter 2024 highlights Financial Attributable net income of $40.6 million or $0.13 per share, compared to a $26.3 million or $0.09 per share in Q1 2024Adjusted attributable net income1 of $30. ...
McEwen Mining: Q2 2024 Results
Newsfilter· 2024-08-08 06:54
TORONTO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- McEwen Mining Inc. (NYSE:MUX) (TSX:MUX) today reported its second quarter (Q2) and half year (H1) results for the period ended June 30th, 2024. "I'm delighted that this quarter was the most profitable since 2016 as measured by Adjusted EBITDA(1) for our mining operations and Q3 is off to a good start. Production costs increased 8% quarter-over-quarter, but revenue grew by 38%. Fox and Gold Bar are capitalizing on the higher gold prices to increase operating cash fl ...
FibroBiologics Files 2024 Second Quarter Report
Newsfilter· 2024-08-08 06:52
HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission. The filing can be viewed through a link on FibroBiologics' website at https:// ...
Quanta Services Announces Pricing of Senior Notes Offering
Prnewswire· 2024-08-08 05:46
HOUSTON, Aug. 7, 2024 /PRNewswire/ -- Quanta Services, Inc. (NYSE: PWR) ("Quanta") announced today the pricing of its offering (the "Offering") of (i) $600,000,000 aggregate principal amount of 4.75% senior notes due 2027 (the "2027 Notes") at a price to the public 99.818% of their face value, and (ii) $650,000,000 aggregate principal amount of 5.25% senior notes due 2034 (the "2034 Notes" and, together with the 2027 Notes, the "Notes") at a price to the public 99.409% of their face value. The Offering is e ...
Avista Corp. Board Declares Common Stock Dividend
Newsfilter· 2024-08-08 05:35
SPOKANE, Wash., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Avista Corp.'s (NYSE: AVA) board of directors has declared a quarterly dividend of $0.475 per share on the company's common stock. The common stock dividend is payable September 13, 2024, to shareholders of record at the close of business on August 22, 2024. The declaration of dividends is at the sole discretion of the board of directors. The board considers the level of dividends on a regular basis, taking into account numerous factors, including financial ...
Tandy Leather Factory Reports Second Quarter 2024 Results
Newsfilter· 2024-08-08 05:35
FORT WORTH, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Tandy Leather Factory, Inc. (Nasdaq: TLF) today announced the Company's financial results for the second fiscal quarter of 2024. Highlights from Second Quarter 2024: Revenues were $17.3 million, down 1.1% from 2023 Generated operating income of $63,000 Net income of $0.1 million, down from $0.5 million in 2023 Gross margins of 58.0%, down from 62.5% in 2023 Operating expenses $10.0 million, down 1.7% from 2023 Adjusted EBITDA* of $0.8 million Ended quarte ...